CytomX Therapeutics (6C1) Earnings Dates, Call Summary & Reports

The P/E ratio of {name} is N/A.

0 Followers

Earnings Data

Report Date

Nov 10, 2026

After Close (Confirmed)

Period Ending

2026 (Q3)

Consensus EPS Forecast

-0.06

Last Year’s EPS

-0.07

Same Quarter Last Year

Strong Buy

Based on 5 Analysts Ratings

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CH:6C1 Upcoming Earnings

CytomX Therapeutics's next earnings date is estimated for November 10, 2026, based on past reporting schedules.

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2026	2026 (Q3)	-0.06 / -	-0.073	―	―	―
Aug 06, 2026	2026 (Q2)	-0.06 / -0.07	0	―	―
May 07, 2026	2026 (Q1)	-0.10 / -0.08	0.22	-137.04% (-0.30)
Mar 16, 2026	2025 (Q4)	-0.08 / -0.14	0.179	-178.64% (-0.32)
Nov 06, 2025	2025 (Q3)	-0.04 / -0.07	0.057	-228.57% (-0.13)	―
Aug 07, 2025	2025 (Q2)	-0.05 / 0.00	-0.065	―	―
May 12, 2025	2025 (Q1)	0.10 / 0.22	0.138	58.82% (+0.08)
Mar 06, 2025	2024 (Q4)	-0.16 / 0.18	0.016	1000.00% (+0.16)	―
Nov 07, 2024	2024 (Q3)	-0.14 / 0.06	0.033	75.00% (+0.02)	―
Aug 08, 2024	2024 (Q2)	-0.08 / -0.07	-0.016	-300.00% (-0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

When does CytomX Therapeutics Inc (CH:6C1) report earnings?

CytomX Therapeutics Inc (CH:6C1) is schdueled to report earning on Nov 10, 2026, After Close (Confirmed).

What is CytomX Therapeutics Inc (CH:6C1) earnings time?

CytomX Therapeutics Inc (CH:6C1) earnings time is at Nov 10, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of CytomX Therapeutics Inc stock?

The P/E ratio of CytomX Therapeutics is N/A.

What is CH:6C1 EPS forecast?

CH:6C1 EPS forecast for the fiscal quarter 2026 (Q3) is -0.06.